
Please try another search
(Reuters) - Nektar Therapeutics (NASDAQ:NKTR) said on Thursday it had stopped all trials involving its key cancer drug following its failure in multiple studies, dragging the drug developer's shares down 23% in after-market trading.
The trials that Nektar stopped included those involving a combination of its drug bempegaldesleukin with Bristol Myers (NYSE:BMY) Squibb Co's cancer drug Opdivo as well Merck & Co Inc's cancer drug Keytruda.
Nektar and Bristol Myers were testing the combination therapy through an agreement signed in 2020, while the one with Keytruda involved a partnership entered with privately owned SFJ Pharmaceuticals last year.
Nektar and Bristol Myers last month discontinued two late-stage studies testing their combination therapy in melanoma patients after one of the trials failed to meet its main goals.
On Thursday, Nektar and Bristol said the combination of drugs failed to meet goals in another late-stage study in patients with renal cell carcinoma, as well as in a study testing the therapy in urothelial carcinoma, a type of bladder cancer.
With Nektar now halting multiple trials of its key drug, the company said it expects to announce a new strategic plan to rein in spending to meet its cash runway goals.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.